Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease

Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE)

Ibrahim Al-Zakwani, Prashanth Panduranga, Jawad A. Al-Lawati, Kadhim Sulaiman, Alawi A. Alsheikh-Ali, Khalid F. AlHabib, Jassim Al Suwaidi, Wael Al-Mahmeed, Hussam AlFaleh, Omar Alnobani, Ahmed Al-Motarreb, Mustafa Ridha, Bassam Bulbanat, Mohammed Al-Jarallah, Nooshin Bazargani, Nidal Asaad, Haitham Amin

Research output: Contribution to journalArticle

Abstract

We evaluated the impact of clopidogrel use on 3- and 12-months all-cause mortality in patients with acute heart failure (AHF) stratified by coronary artery disease (CAD) in patients admitted to 47 hospitals in 7 Middle Eastern countries with AHF from February to November 2012. Clopidogrel use was associated with significantly lower risk of all-cause mortality at 3 months (adjusted odds ratio [aOR], 0.61; 95% confidence interval [CI]: 0.42-0.87; P =.007) and 12 months (aOR, 0.61; 95% CI: 0.47-0.79; P <.001). When the analysis was stratified by CAD, the clopidogrel group in those with AHF and CAD was also associated with significantly lower risk of all-cause mortality at 3 months (aOR, 0.56; 95% CI: 0.38-0.83; P =.003) and 12 months (aOR, 0.58; 95% CI: 0.44-0.77; P <.001). However, in AHF patients without CAD, clopidogrel use was not associated with any survival advantages, neither at 3 months (aOR, 0.99; 95% CI: 0.32-3.11; P =.987) nor at 12 months (aOR, 0.80; 95% CI: 0.37-1.72; P =.566). Clopidogrel use was associated with short- and long-term all-cause mortality in patients with AHF and CAD. In AHF patients without CAD, clopidogrel use did not offer any survival advantage.

Original languageEnglish
Pages (from-to)884-891
Number of pages8
JournalAngiology
Volume69
Issue number10
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

clopidogrel
Registries
Coronary Artery Disease
Heart Failure
Odds Ratio
Confidence Intervals
Mortality
Survival

Keywords

  • Arabs
  • clopidogrel
  • coronary artery disease
  • heart failure
  • Middle East
  • mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease : Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE). / Al-Zakwani, Ibrahim; Panduranga, Prashanth; Al-Lawati, Jawad A.; Sulaiman, Kadhim; Alsheikh-Ali, Alawi A.; AlHabib, Khalid F.; Suwaidi, Jassim Al; Al-Mahmeed, Wael; AlFaleh, Hussam; Alnobani, Omar; Al-Motarreb, Ahmed; Ridha, Mustafa; Bulbanat, Bassam; Al-Jarallah, Mohammed; Bazargani, Nooshin; Asaad, Nidal; Amin, Haitham.

In: Angiology, Vol. 69, No. 10, 01.11.2018, p. 884-891.

Research output: Contribution to journalArticle

Al-Zakwani, I, Panduranga, P, Al-Lawati, JA, Sulaiman, K, Alsheikh-Ali, AA, AlHabib, KF, Suwaidi, JA, Al-Mahmeed, W, AlFaleh, H, Alnobani, O, Al-Motarreb, A, Ridha, M, Bulbanat, B, Al-Jarallah, M, Bazargani, N, Asaad, N & Amin, H 2018, 'Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease: Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE)', Angiology, vol. 69, no. 10, pp. 884-891. https://doi.org/10.1177/0003319718775552
Al-Zakwani, Ibrahim ; Panduranga, Prashanth ; Al-Lawati, Jawad A. ; Sulaiman, Kadhim ; Alsheikh-Ali, Alawi A. ; AlHabib, Khalid F. ; Suwaidi, Jassim Al ; Al-Mahmeed, Wael ; AlFaleh, Hussam ; Alnobani, Omar ; Al-Motarreb, Ahmed ; Ridha, Mustafa ; Bulbanat, Bassam ; Al-Jarallah, Mohammed ; Bazargani, Nooshin ; Asaad, Nidal ; Amin, Haitham. / Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease : Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE). In: Angiology. 2018 ; Vol. 69, No. 10. pp. 884-891.
@article{25aa4fd9a93b48fcaff330d5c248a7b5,
title = "Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease: Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE)",
abstract = "We evaluated the impact of clopidogrel use on 3- and 12-months all-cause mortality in patients with acute heart failure (AHF) stratified by coronary artery disease (CAD) in patients admitted to 47 hospitals in 7 Middle Eastern countries with AHF from February to November 2012. Clopidogrel use was associated with significantly lower risk of all-cause mortality at 3 months (adjusted odds ratio [aOR], 0.61; 95{\%} confidence interval [CI]: 0.42-0.87; P =.007) and 12 months (aOR, 0.61; 95{\%} CI: 0.47-0.79; P <.001). When the analysis was stratified by CAD, the clopidogrel group in those with AHF and CAD was also associated with significantly lower risk of all-cause mortality at 3 months (aOR, 0.56; 95{\%} CI: 0.38-0.83; P =.003) and 12 months (aOR, 0.58; 95{\%} CI: 0.44-0.77; P <.001). However, in AHF patients without CAD, clopidogrel use was not associated with any survival advantages, neither at 3 months (aOR, 0.99; 95{\%} CI: 0.32-3.11; P =.987) nor at 12 months (aOR, 0.80; 95{\%} CI: 0.37-1.72; P =.566). Clopidogrel use was associated with short- and long-term all-cause mortality in patients with AHF and CAD. In AHF patients without CAD, clopidogrel use did not offer any survival advantage.",
keywords = "Arabs, clopidogrel, coronary artery disease, heart failure, Middle East, mortality",
author = "Ibrahim Al-Zakwani and Prashanth Panduranga and Al-Lawati, {Jawad A.} and Kadhim Sulaiman and Alsheikh-Ali, {Alawi A.} and AlHabib, {Khalid F.} and Suwaidi, {Jassim Al} and Wael Al-Mahmeed and Hussam AlFaleh and Omar Alnobani and Ahmed Al-Motarreb and Mustafa Ridha and Bassam Bulbanat and Mohammed Al-Jarallah and Nooshin Bazargani and Nidal Asaad and Haitham Amin",
year = "2018",
month = "11",
day = "1",
doi = "10.1177/0003319718775552",
language = "English",
volume = "69",
pages = "884--891",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease

T2 - Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE)

AU - Al-Zakwani, Ibrahim

AU - Panduranga, Prashanth

AU - Al-Lawati, Jawad A.

AU - Sulaiman, Kadhim

AU - Alsheikh-Ali, Alawi A.

AU - AlHabib, Khalid F.

AU - Suwaidi, Jassim Al

AU - Al-Mahmeed, Wael

AU - AlFaleh, Hussam

AU - Alnobani, Omar

AU - Al-Motarreb, Ahmed

AU - Ridha, Mustafa

AU - Bulbanat, Bassam

AU - Al-Jarallah, Mohammed

AU - Bazargani, Nooshin

AU - Asaad, Nidal

AU - Amin, Haitham

PY - 2018/11/1

Y1 - 2018/11/1

N2 - We evaluated the impact of clopidogrel use on 3- and 12-months all-cause mortality in patients with acute heart failure (AHF) stratified by coronary artery disease (CAD) in patients admitted to 47 hospitals in 7 Middle Eastern countries with AHF from February to November 2012. Clopidogrel use was associated with significantly lower risk of all-cause mortality at 3 months (adjusted odds ratio [aOR], 0.61; 95% confidence interval [CI]: 0.42-0.87; P =.007) and 12 months (aOR, 0.61; 95% CI: 0.47-0.79; P <.001). When the analysis was stratified by CAD, the clopidogrel group in those with AHF and CAD was also associated with significantly lower risk of all-cause mortality at 3 months (aOR, 0.56; 95% CI: 0.38-0.83; P =.003) and 12 months (aOR, 0.58; 95% CI: 0.44-0.77; P <.001). However, in AHF patients without CAD, clopidogrel use was not associated with any survival advantages, neither at 3 months (aOR, 0.99; 95% CI: 0.32-3.11; P =.987) nor at 12 months (aOR, 0.80; 95% CI: 0.37-1.72; P =.566). Clopidogrel use was associated with short- and long-term all-cause mortality in patients with AHF and CAD. In AHF patients without CAD, clopidogrel use did not offer any survival advantage.

AB - We evaluated the impact of clopidogrel use on 3- and 12-months all-cause mortality in patients with acute heart failure (AHF) stratified by coronary artery disease (CAD) in patients admitted to 47 hospitals in 7 Middle Eastern countries with AHF from February to November 2012. Clopidogrel use was associated with significantly lower risk of all-cause mortality at 3 months (adjusted odds ratio [aOR], 0.61; 95% confidence interval [CI]: 0.42-0.87; P =.007) and 12 months (aOR, 0.61; 95% CI: 0.47-0.79; P <.001). When the analysis was stratified by CAD, the clopidogrel group in those with AHF and CAD was also associated with significantly lower risk of all-cause mortality at 3 months (aOR, 0.56; 95% CI: 0.38-0.83; P =.003) and 12 months (aOR, 0.58; 95% CI: 0.44-0.77; P <.001). However, in AHF patients without CAD, clopidogrel use was not associated with any survival advantages, neither at 3 months (aOR, 0.99; 95% CI: 0.32-3.11; P =.987) nor at 12 months (aOR, 0.80; 95% CI: 0.37-1.72; P =.566). Clopidogrel use was associated with short- and long-term all-cause mortality in patients with AHF and CAD. In AHF patients without CAD, clopidogrel use did not offer any survival advantage.

KW - Arabs

KW - clopidogrel

KW - coronary artery disease

KW - heart failure

KW - Middle East

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=85054401002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054401002&partnerID=8YFLogxK

U2 - 10.1177/0003319718775552

DO - 10.1177/0003319718775552

M3 - Article

VL - 69

SP - 884

EP - 891

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 10

ER -